Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJun 10, 2026
DataAggregated Company Financials
Companies20
  • 7D-1.9%
  • 3M6.2%
  • 1Y-42.3%
  • YTD-17.4%

Over the last 7 days, the Healthcare industry has dropped 3.7%, driven by a pullback from Novo Nordisk of 2.8%. Overall the industry is down 39% in 12 months. Earnings are forecast to grow by 3.2% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 10 Jun 2026DKK 1.6tDKK 468.9bDKK 147.1b19.8x11x3.4x
Fri, 08 May 2026DKK 1.7tDKK 466.4bDKK 149.5b20.7x11.5x3.7x
Sun, 05 Apr 2026DKK 1.5tDKK 447.8bDKK 130.1b17.4x11.3x3.3x
Tue, 03 Mar 2026DKK 1.5tDKK 447.7bDKK 130.9b18.7x11.5x3.3x
Thu, 29 Jan 2026DKK 2.2tDKK 453.2bDKK 136.7b17.7x15.9x4.8x
Sat, 27 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Mon, 24 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b17.1x13.5x4.1x
Wed, 22 Oct 2025DKK 2.1tDKK 447.6bDKK 141.8b19.2x14.9x4.7x
Fri, 19 Sep 2025DKK 2.2tDKK 447.2bDKK 141.6b19.1x15.8x5x
Sun, 17 Aug 2025DKK 1.9tDKK 444.4bDKK 140.2b28.1x13.6x4.3x
Tue, 15 Jul 2025DKK 2.4tDKK 423.2bDKK 124.5b29.9x19.4x5.7x
Thu, 12 Jun 2025DKK 2.8tDKK 423.6bDKK 124.6b31.3x22.3x6.6x
Sat, 10 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Mon, 07 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b22.8x19.4x5.8x
Wed, 05 Mar 2025DKK 3.3tDKK 410.0bDKK 121.4b26.9x26.8x7.9x
Fri, 31 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b28.6x29.2x8.4x
Sun, 29 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Tue, 26 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31.2x34.7x10x
Thu, 24 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b34.2x38.4x11.1x
Sat, 21 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Mon, 19 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.2x43.9x12.7x
Wed, 17 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.2x46.1x13.8x
Fri, 14 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b36.4x46.6x13.9x
Sun, 12 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Tue, 09 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.9x13.1x
Thu, 07 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38.2x44.3x12.9x
Sat, 03 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Mon, 01 Jan 2024DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Wed, 29 Nov 2023DKK 3.6tDKK 320.4bDKK 90.0b33x39.7x11.2x
Fri, 27 Oct 2023DKK 3.5tDKK 305.7bDKK 82.3b26.7x42.5x11.4x
Sun, 24 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Tue, 22 Aug 2023DKK 3.3tDKK 303.6bDKK 81.3b36.3x40.8x10.9x
Thu, 20 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.7x10.2x
Sat, 17 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Price to Earnings Ratio

40.3x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.0x which is lower than its 3-year average PE of 29.9x.
  • The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-1.29%
Healthcare-1.87%
Life Sciences2.95%
Medical Equipment2.14%
Biotech1.65%
Healthtech-0.72%
Pharma-2.76%
Healthcare Services-6.04%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.1x.
    • Analysts are expecting annual earnings growth of 20.1%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.2% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.61k4.3%
+DKK 4.1b		7.7%PE18.6x
COLO B ColoplastDKK 386.702.3%
+DKK 2.0b		-39.3%PE41.3x
DEMANT DemantDKK 256.002.6%
+DKK 1.3b		-7.9%PE22.8x
ALK B ALK-AbellóDKK 264.001.0%
+DKK 576.1m		42.9%PE45.7x
CHEMM ChemoMetecDKK 383.604.8%
+DKK 306.3m		-30.7%PE37.7x

Latest News

BAVA
DKK 182.30
Bavarian Nordic
7D
-0.2%
1Y
-3.0%
NOVO B
DKK 269.50
Novo Nordisk
7D
-2.9%
1Y
-48.2%
ZEAL
DKK 278.90
Zealand Pharma
7D
-8.5%
1Y
-43.9%
HLUN B
DKK 43.00
H. Lundbeck
7D
-2.8%
1Y
8.0%
Narrative Update • Jun 06

HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple

Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.
EMBLA
DKK 27.30
Embla Medical hf
7D
1.1%
1Y
-19.7%
Narrative Update • Jun 06

EMBLA: Ongoing Buybacks And Share Cancellations Will Support Future Upside

Analysts have kept their DKK price target for Embla Medical hf. broadly unchanged, with only a marginal adjustment driven by a slightly lower discount rate and a small tweak to the assumed future P/E multiple.
DEMANT
DKK 256.00
Demant
7D
2.6%
1Y
-7.9%
Narrative Update • Jun 05

DEMANT: Raised Fair Value And EU AI Rules May Shape Re Rating

Analysts have lifted the fair value estimate for Demant from DKK 229.83 to DKK 240.32. This reflects updated targets from firms such as Deutsche Bank and Morgan Stanley and is supported by assumptions for slightly higher revenue growth, improved profit margins, and a modestly lower discount rate, while keeping future P/E expectations broadly unchanged.
COLO B
DKK 386.70
Coloplast
7D
2.3%
1Y
-39.3%
AMBU B
DKK 65.00
Ambu
7D
0.7%
1Y
-36.4%
Narrative Update • Jun 03

AMBU B: Bearish Street Sentiment Will Support Future Upside Repricing

Analysts have reduced their price target on Ambu to DKK 88.8, citing a more cautious stance reflected in recent bearish Street research and downgrades. What's in the News Analysts have adopted a more cautious stance on Ambu, reflected in recent bearish research and rating downgrades from the Street.
GMAB
DKK 1,610.50
Genmab
7D
4.3%
1Y
7.7%
ALK B
DKK 264.00
ALK-Abelló
7D
1.0%
1Y
42.9%
Narrative Update • May 29

ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership

Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.
GUBRA
DKK 337.00
Gubra
7D
0.8%
1Y
-37.6%
Narrative Update • May 26

GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside

Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.
SMSMED
DKK 2.80
Scandinavian Medical Solutions
7D
-6.0%
1Y
-38.9%
BIOPOR
DKK 1.20
BioPorto
7D
-9.5%
1Y
-13.4%
NNIT
DKK 39.85
NNIT
7D
-1.1%
1Y
-44.3%
CHEMM
DKK 383.60
ChemoMetec
7D
4.8%
1Y
-30.7%
PEG
DKK 0.07
Pharma Equity Group
7D
-1.7%
1Y
-34.0%